Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Senetek (SNTK) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (21)	1/30/2003 8:38:34 PM
From: SemiBull	Read Replies (1) \| Respond to of 101

Dr. Brian Clark, One of Senetek's Founders and Co-Discoverer of Its Proprietary Cytokinins, to Lead Research and Development Wednesday January 29, 8:05 am ET NAPA, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), ( www.senetekplc.com ), announced today that Dr. Brian Clark, one of the founders of Senetek and co-discoverer of its proprietary skincare compounds, Kinetin and Zeatin, has agreed to lead Senetek's Research and Development program as Chief Scientist. Dr. Clark will be headquartered in Aarhus, Denmark, where the Company currently has a collaboration with the University of Aarhus and sponsors a Research Professorship. Dr. Clark's first objectives will be to restructure the research organization at Senetek and work towards bringing other proprietary compounds to the Company. Frank J. Massino, Chairman and Chief Executive Officer, stated, "We are delighted to have a scientist of Dr. Clark's caliber assume the leadership of Senetek's research and development programs. We had been in discussions over the past several years and the timing could not be better for Dr. Clark to take on this role now that we are financially stabilized and placing our emphasis on enhancing shareholder value by expanding our acquisition and development of new technologies." Dr. Clark is the President of The International Union of Biochemistry and Molecular Biology and heads up the Danish Centre for Molecular Gerontology. Dr. Clark received his Ph.D. in Organic Chemistry from Cambridge University in 1961 and his Doctorate of Science degree (Sc.D) in Molecular Biology from Cambridge University in 1975. Among his many achievements are the Discovery of the Initiation Codon for protein synthesis and hence the start of protein coding (1965 and 1966) the first crystallization of tRNA (1968) and Project leader for X-ray crystallographic structural determination of translation factors and complexes, 1974 through 1994. Dr. Clark is a founding member of the Editorial Board of the European Molecular Biology Organization (EMBO) Journal and a member of the Editorial Boards of Biochimie and the International Union of Biochemistry and Molecular Biology Life Journal. Dr. Clark has over 200 publications in print. Dr. Clark has received numerous Honours to include: Foreign Member of the Royal Danish Academy of Sciences and Letters; Member of European Molecular Biology Organization (EMBO); Honorary Member of the Hellenic Biochemical and Biophysical Society; and Honorary Doctorate from the Engelhardt Institute of Molecular Biology, Moscow and others. Senetek PLC is a healthcare technologies company focused on developing and co-marketing products applicable to the anti-aging markets in key skin care/dermatologicals and sexual dysfunction categories worldwide. * Visit Senetek PLC's web site: senetekplc.com. * Senetek PLC Investor Relations Contact: 1-707-226-3900 ext. 102 E-Mail: Pknopick@eandecommunications.com Safe Harbor Statement: This news release may contain statements that may be considered "forward- looking statements" under the Federal securities laws, including statements concerning the revenue and licensing income the Company may receive in the future under licenses of the Company's products, and the additional licensing agreements the Company may enter into during 2003. No forward-looking statement the Company makes is a guarantee of future performance or events. Actual results or events may differ materially from those in the forward- looking statements as a result of various factors, including the risks and uncertainties described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and Quarterly Report on Form 10-Q for the three months ended September 30, 2002, filed with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Source: Senetek PLC